MedPath

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA

Not Applicable
Completed
Conditions
Hiv
Sexually Transmitted Infection
Registration Number
NCT05504954
Lead Sponsor
University of Illinois at Chicago
Brief Summary

Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets. Informed, Motivated, Aware and Responsible Adolescents and Adults- South Africa (IMARA-SA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. This pilot study will assess feasibility in preparation for a randomized controlled trial (RCT). Additionally, the pilot will examine the preliminary effectiveness of IMARA-SA in reducing sexually transmitted infections (STI) and increasing uptake of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at follow-up among AGYW. About 60 AGYW-FC dyads will be enrolled and randomized to IMARA-SA or a health-promotion control arm. Following randomization, the dyads will participate in an \~2-day group workshop (\~10 hours), which includes joint and separate mother and daughter activities. AGYW and FC will complete baseline assessments and follow-up assessments approximately 6 months later. Assessments will include surveys, STIs testing (for chlamydia and gonorrhea), and uptake of HTC and a 1-month PrEP prescription. Additionally, the intervention's implementation (e.g., acceptability) will be explored.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
61
Inclusion Criteria

Not provided

Exclusion Criteria

AGYW will be excluded from the study if they do not have a FC to participate in the study.

AGYW and FC will be excluded from the study if they:

  1. are unable to understand the consent/assent process and provide written informed consent;
  2. are currently enrolled in another research study addressing HIV/STIs/PrEP;
  3. participated in the IMARA-SA adaptation process. AGYW and FC must agree to participate as a dyad. AGYW refusal will supersede FC consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI)8-17 months post baseline

A positive test for at least one of two STIs: chlamydia and/or gonorrhea

Number of AGYW Completing HIV Testing and Counseling (HTC)8-17 months post baseline

Completion of HIV Testing and Counseling (HTC)

Number of AGYW Who Elected to Take Pre-Exposure Prophylaxis (PrEP)8-17 months post baseline

Uptake of Pre-Exposure Prophylaxis (PrEP) assessed as receipt of PrEP prescription from research team or other care provider after the baseline survey.

Secondary Outcome Measures
NameTimeMethod
AGYW Condom Use at Last Sex6-10 months post baseline

Self-reported condom use at last vaginal or anal sex using the AIDS Risk Behavior Assessment (ARBA).

AGYW Consistency of Condom Use6-10 months post baseline

Self-reported consistency of condom use during vaginal and anal sex in the past 6-months using the AIDS Risk Behavior Assessment (ARBA).

AGYW Substance Use During Sex in the Past 6 Months6-10 months post baseline

Self-reported number of times had vaginal or anal sex while drinking or taking drugs in the past 6-months using the AIDS Risk Behavior Assessment (ARBA).

Number of Partners in the Past 6 Months6-10 months post baseline

Self-reported number of vaginal or anal sex partners in the past 6-months using the AIDS Risk Behavior Assessment (ARBA).

AGYW's Report of Adherence to PrEP6-10 months post baseline

Adherence to PrEP is measured using an adapted version of the Wilson scale (2017).

Measure Description: (0=low adherence to 100=high adherence) Scale is comprised of 3 items: number of days dose missed, how often did you take PrEP in the way you were supposed to, how good a job did you do at taking PrEP.

Items were transformed to a 0-100 scale and averaged. Thirty was subtracted from number of days missed and multiplied by 3.33. Responses for remaining 2 items: never/very poor=0, rarely/poor=20, sometimes/fair=40, usually/good=60, almost always/very good=80, always/excellent=100.

Trial Locations

Locations (1)

Desmond Tutu HIV Centre

🇿🇦

Cape Town, Western Cape, South Africa

Desmond Tutu HIV Centre
🇿🇦Cape Town, Western Cape, South Africa

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.